FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999685584> ?p ?o ?g. }

• W2999685584 endingPage "109661" @default.
• W2999685584 startingPage "109661" @default.
• W2999685584 abstract "Ovarian cancer is the most lethal gynecologic malignancy and the fifth most lethal cancer type overall in women. Ovarian cancer often presents genome instability, with almost half of the ovarian cancers harbor defects in one or more of the six DNA repair pathways, most of them in homologous recombination (HR). Targeting DNA repair genes has becoming a unique strategy to combat HR-deficient cancers in recent years. The multi-functional enzyme Poly ADP ribose polymerase (PARP) plays an impart role in DNA damage repair and genome stability. PARP inhibitors inhibit DNA repair pathways and cause apoptosis of cancer cells, especially in homologous recombination (HR)-deficient cells. PARP inhibitors (PARPi) have drawn increasing amount of attention due to their remarkable efficacy and low toxicity in treating HR-deficient ovarian cancers (i.e. BRCA1/2 mutated). To date, three PARP inhibitor drugs have been approved for treating ovarian cancer by FDA in United States, namely Olaparib, Rucaparib, and Niraparib. In this review, we summarized the current research progress of PARPi from basic science to clinical studies. We discussed the mechanism of action of PARP inhibitors and the exciting results from the clinical studies of the FDA-approved PARP inhibitors. We also highlighted the current research progress on PARP inhibitor resistance, which has become a challenge in clinics." @default.
• W2999685584 created "2020-01-23" @default.
• W2999685584 creator A5012587305 @default.
• W2999685584 creator A5022604913 @default.
• W2999685584 creator A5044544424 @default.
• W2999685584 creator A5078024000 @default.
• W2999685584 creator A5081268487 @default.
• W2999685584 creator A5083407152 @default.
• W2999685584 date "2020-03-01" @default.
• W2999685584 modified "2023-09-27" @default.
• W2999685584 title "Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer" @default.
• W2999685584 cites W1757407923 @default.
• W2999685584 cites W1841331176 @default.
• W2999685584 cites W1969262167 @default.
• W2999685584 cites W1973268287 @default.
• W2999685584 cites W1978780879 @default.
• W2999685584 cites W1982957001 @default.
• W2999685584 cites W1989006164 @default.
• W2999685584 cites W1989996784 @default.
• W2999685584 cites W1990734482 @default.
• W2999685584 cites W2009007206 @default.
• W2999685584 cites W2014599726 @default.
• W2999685584 cites W2015360671 @default.
• W2999685584 cites W2020991778 @default.
• W2999685584 cites W2025047585 @default.
• W2999685584 cites W2027379868 @default.
• W2999685584 cites W2058957446 @default.
• W2999685584 cites W2067117419 @default.
• W2999685584 cites W2070758111 @default.
• W2999685584 cites W2073569331 @default.
• W2999685584 cites W2081183202 @default.
• W2999685584 cites W2083960841 @default.
• W2999685584 cites W2086038769 @default.
• W2999685584 cites W2090968329 @default.
• W2999685584 cites W2091230697 @default.
• W2999685584 cites W2096380982 @default.
• W2999685584 cites W2100525241 @default.
• W2999685584 cites W2102752109 @default.
• W2999685584 cites W2113125265 @default.
• W2999685584 cites W2114787582 @default.
• W2999685584 cites W2116804853 @default.
• W2999685584 cites W2117964602 @default.
• W2999685584 cites W2118211359 @default.
• W2999685584 cites W2123696077 @default.
• W2999685584 cites W2141579854 @default.
• W2999685584 cites W2150594642 @default.
• W2999685584 cites W2160234594 @default.
• W2999685584 cites W2160466424 @default.
• W2999685584 cites W2168169655 @default.
• W2999685584 cites W2168396953 @default.
• W2999685584 cites W2179105349 @default.
• W2999685584 cites W2406538768 @default.
• W2999685584 cites W2472306545 @default.
• W2999685584 cites W2473878031 @default.
• W2999685584 cites W2476568892 @default.
• W2999685584 cites W2517053206 @default.
• W2999685584 cites W2528228811 @default.
• W2999685584 cites W2528536528 @default.
• W2999685584 cites W2539944286 @default.
• W2999685584 cites W2562712448 @default.
• W2999685584 cites W2570618306 @default.
• W2999685584 cites W2594301310 @default.
• W2999685584 cites W2597062310 @default.
• W2999685584 cites W2623263876 @default.
• W2999685584 cites W2731295019 @default.
• W2999685584 cites W2732346161 @default.
• W2999685584 cites W2737389832 @default.
• W2999685584 cites W2737658553 @default.
• W2999685584 cites W2741214285 @default.
• W2999685584 cites W2754327139 @default.
• W2999685584 cites W2761228804 @default.
• W2999685584 cites W2765667278 @default.
• W2999685584 cites W2767593721 @default.
• W2999685584 cites W2788106879 @default.
• W2999685584 cites W2795708528 @default.
• W2999685584 cites W2803857309 @default.
• W2999685584 cites W2807649309 @default.
• W2999685584 cites W2808113406 @default.
• W2999685584 cites W2883664363 @default.
• W2999685584 cites W2884164644 @default.
• W2999685584 cites W2886477543 @default.
• W2999685584 cites W2890799019 @default.
• W2999685584 cites W2891719366 @default.
• W2999685584 cites W2892812402 @default.
• W2999685584 cites W2894321113 @default.
• W2999685584 cites W2897369942 @default.
• W2999685584 cites W2899163437 @default.
• W2999685584 cites W2900139029 @default.
• W2999685584 cites W2902886329 @default.
• W2999685584 cites W2905535260 @default.
• W2999685584 cites W2908112515 @default.
• W2999685584 cites W2944149590 @default.
• W2999685584 cites W2951673912 @default.
• W2999685584 cites W2967738649 @default.
• W2999685584 cites W2976139792 @default.
• W2999685584 cites W4211203170 @default.
• W2999685584 cites W4251913774 @default.
• W2999685584 doi "https://doi.org/10.1016/j.biopha.2019.109661" @default.

• next